at://
/
app.bsky.feed.post
/
3mo3ixhn3es2u
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
PostEmbed
Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...
www.ipharmacenter.com
Takeda's Zasocitinib achieved over 2.5 times the PASI 100 rate of deucravacitinib in a head‑to‑head Ph3 psoriasis trial | iPharmaCenter